NCT04839965View on ClinicalTrials.gov

Study of Intravenous Ampion in Adult COVID-19 Patients Requiring Supplemental Oxygen

PHASE2TerminatedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 5, 2021

Primary Completion Date

February 7, 2022

Study Completion Date

April 4, 2022

Conditions
COVID-19
Interventions
BIOLOGICAL

Ampion

Ampion administered via intravenous infusion

OTHER

Saline

Placebo administered via intravenous infusion

Trial Locations (1)

80112

Ampio Pharmaceuticals, Englewood

Sponsors
All Listed Sponsors
lead

Ampio Pharmaceuticals. Inc.

INDUSTRY

NCT04839965 - Study of Intravenous Ampion in Adult COVID-19 Patients Requiring Supplemental Oxygen | Biotech Hunter | Biotech Hunter